Top

Molecular Imaging and Biology

Published in:

01-02-2011 | Research Article

Comparison of FLT-PET and FDG-PET for Visualization of Head and Neck Squamous Cell Cancers

Authors: Hiroshi Hoshikawa, Yoshihiro Nishiyama, Takehito Kishino, Yuka Yamamoto, Reiji Haba, Nozomu Mori

Published in: Molecular Imaging and Biology | Issue 1/2011

Abstract

Purpose

We compared 3'[F-18]fluoro-3'-deoxythymidine (FLT) positron emission tomography (PET) and 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) for PET visualization of head and neck squamous cell cancers (HNSCCs) and evaluated which might better reflect proliferative activity as indicated by the Ki-67 index.

Procedures

A total of 43 patients with HNSCCs were examined with FLT-PET and FDG-PET. The PET images were evaluated qualitatively for regions of focally increased metabolism and for semiquantitative analysis the maximum standardized uptake value (SUV) was calculated.

Results

For depiction of primary tumours, the sensitivity of both approaches was 100%. The mean (±SD) SUV for FLT (5.65 ± 2.96) was significantly lower than that for FDG (10.9 ± 4.91; p < 0.0001). No significant differences were found for the T category. However, the mean (±SD) FLT SUV was significantly higher in poorly than in well-differentiated tumours (6.49 ± 3.13 vs. 4.2 ± 2.08; p < 0.04). Similarly, FDG SUVs in poorly and moderately differentiated tumours (12.72 ± 4.8 and 11.46 ± 4.64) were significantly higher than in well-differentiated tumours (7.45 ± 3.51; p < 0.004 and p < 0.02). No significant correlation was observed with the Ki-67 index for either.

Conclusion

FLT-PET showed as high a sensitivity as FDG-PET for the detection of primary HNSCC lesions, although uptake of FLT was significantly lower than that of FDG.

Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305–332CrossRefPubMed

Laubenbacher C, Saumweber D, Wagner-Manslau C et al (1995) Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 36:1747–1757PubMed

Klabbers BM, Lammertsma AA, Slotman BJ (2003) The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Mol Imaging Biol 5:257–270CrossRefPubMed

Greven KM, Williams DW 3rd, McGuirt WF Sr et al (2001) Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23:942–946CrossRefPubMed

Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eue J Nucl Med 2:1409–1415CrossRef

Kubota K (2001) From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 15:471–486CrossRefPubMed

Ac B, Schirrmeister HH, Guhlmann CA et al (2001) Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 42:721–725

Shields AF, Larson SM, Grunbaum Z, Graham MM (1984) Short-term thymidine uptake in normal and neoplastic tissues: studies for PET. J Nucl Med 25:759–764PubMed

Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JC (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43:1210–1217PubMed

10.

Francis DL, Freeman A, Visvikis D et al (2003) In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52:1602–1606CrossRefPubMed

11.

van Westreenen H, Cobben DCP, Jager PL et al (2005) Comparison of ¹⁸F-FLT PET and ¹⁸F-FDG PET in esophageal cancer. J Nucl Med 46:400–404PubMed

12.

Smyczek-Gargya B, Fersis N, Dittmann H et al (2004) PET with [¹⁸F] fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31:720–724CrossRefPubMed

13.

Yamamoto Y, Nishiyama Y, Ishikawa S et al (2007) Correlation of ¹⁸F-FLT and ¹⁸F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34:1610–1616CrossRefPubMed

14.

Cobben DC, Van der Laan BF, Maas B et al (2004) ¹⁸F-FLT PET for visualization of laryngeal cancer: comparison with ¹⁸F-FDG PET. J Nucl Med 45:226–231PubMed

15.

Linecker A, Kermer C, Sulzbacher I et al (2008) Uptake of ¹⁸F-FLT and ¹⁸F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin 47:80–85PubMed

16.

Sobin LH, Wittekind Ch (eds) (1997) UICC: TNM classification of malignant tumours, 5th edn. Wiley-Liss, New York

17.

Machulla HJ, Blocher A, Kuntzsch M, Grierson JR (2000) Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Ch 24:843–846CrossRef

18.

Minn H, Lapela M, Klemi PJ et al (1997) Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38:1907–1911PubMed

19.

Slevin NJ, Collins CD, Hastings DL et al (1999) The diagnostic value of positron emission tomography (PET) with radiolabelled fluorodeoxyglucose (¹⁸F-FDG) in head and neck cancer. J Laryngol Otol 113:548–554CrossRefPubMed

20.

Kameyama R, Yamamoto Y, Izuishi K et al (2009) Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 36:382–388CrossRefPubMed

21.

Barthel H, Cleij MC, Collingridge DR et al (2003) 3′-deoxy-3′-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63:3791–3798PubMed

22.

Apisarnthanarax S, Alauddin MM, Mourtada F et al (2006) Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 12:4590–4597CrossRefPubMed

23.

Troost EG, Vogel WV, Merkx MA et al (2007) 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48:726–735CrossRefPubMed

24.

Pio BS, Park CK, Pietras R et al (2006) Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8:36–42CrossRefPubMed

25.

Herrmann K, Wieder HA, Buck AK et al (2007) Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin’s lymphoma. Clin Clin Cancer Res 13:3552–3558CrossRef

26.

Yang YJ, Ryu JS, Kim SY et al (2006) Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 33:412–419CrossRefPubMed

Title: Comparison of FLT-PET and FDG-PET for Visualization of Head and Neck Squamous Cell Cancers
Authors: Hiroshi Hoshikawa
Yoshihiro Nishiyama
Takehito Kishino
Yuka Yamamoto
Reiji Haba
Nozomu Mori
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 1/2011
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-010-0331-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of FLT-PET and FDG-PET for Visualization of Head and Neck Squamous Cell Cancers

Abstract

Purpose

Procedures

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2011

Practice Based Evidence of the Beneficial Impact of PET in Patients with Brain Tumors

In Vivo Mouse Bioluminescence Tomography with Radionuclide-Based Imaging Validation

Plasma Protein Binding of Luciferase Substrates Influences Sensitivity and Accuracy of Bioluminescence Imaging

Replacing Vascular Corrosion Casting by In Vivo Micro-CT Imaging for Building 3D Cardiovascular Models in Mice

[(Methyl)1-11C]-Acetate Metabolism in Hepatocellular Carcinoma

Reduced PBR/TSPO Expression After Minocycline Treatment in a Rat Model of Focal Cerebral Ischemia: A PET Study Using [18F]DPA-714